How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

Abstract excerpt

In recent years there have been major advances in the use of molecular diagnostic and monitoring techniques for patients with acute myeloid leukaemia (AML). Coupled with the simultaneous explosion of new therapeutic agents, this has sown the seeds for significant improvements to treatment algorithms. Here we show, using a selection of real-life examples, how molecular monitoring can be used to refine clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allografts
• Share to Clinical Decision-Making
• Share to Core Binding Factors